PhagoMed has been named a Healthcare Category Finalist in the Extreme Tech Challenge 2021. The company was selected out of more than...

Among more than 500 applicants, PhagoMed was selected in autumn 2020 to participate in the Endless Frontiers Lab (EFL) acceleration...

PhagoMed published details on its phage program PM-399 including a detailed introduction to its proprietary ɛ2-(evolution...

PhagoMed partnered with Yale University and the University of Maryland School of Medicine to provide intra-articular phage therapy to a...

Since June 2020, PhagoMed has been part of the Gold Track program, the premier European life sciences accelerator. Following the...

An engineered phage endolysin could offer a highly innovative and precise therapy for recurrent bacterial vaginosis, a disease for which...

PhagoMed Biopharma GmbH came 2nd and won €20.000 in one of the toughest contests for young European biotech companies, namely the Health...

Earlier this year, PhagoMed was selected to compete at the Hello Tomorrow Global Challenge 2020 in 'Medical Biotech' track. The...

Press Release, Vienna (Austria), 28th October 2020: An engineered phage endolysin could offer a highly innovative and precise therapy for...